People want drug industry oversight

Share this article:
US adults want information on and oversight of the drug industry, according to a recent Harris Poll. Poll officials said 71% of adults surveyed believe it is very important or highly important that marketed drugs remain under close review by the FDA and drug companies. Only 9% of respondents said such review is only somewhat or not very important.

The researchers said many Americans are demonstrating consumerism by seeking information on drug safety, with 41% of those surveyed saying they always or often seek information on drug safety for themselves or family members.

Another 35% said they sometimes seek drug safety information, while only 24% said they rarely or never look for safety information.

There were age differences in the responses, with those who are older more likely to be concerned about drug safety.

“The public's desire for drug safety information and their belief that drugs should remain under continued review by FDA and drug companies indicates that Americans may have concerns regarding the full safety profile of all drugs,” the pollsters said. “These questions on safety may be negatively affecting their impressions of the industry…Ultimately, the findings continue to highlight the need for drug companies to build and maintain consumer confidence as a key component of their overall corporate reputation.”

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.